Celltrion targets wider European growth for Omlyclo after gains in Spain, Italy

Celltrion is stepping up efforts to expand sales of its omalizumab biosimilar Omlyclo across Europe, building on an estimated market share exceeding 90 percent in Spain and sales above its business target in Italy, the company said Thursday.Omlyclo, used to treat chronic spontaneous urticaria and alRead More